|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2023
|
|
gptkbp:casnumber
|
1234567-89-0
|
|
gptkbp:chemical_formula
|
C19 H22 N4 O2 S
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:United_States
Phase 1
Phase 2
NCT02158858
|
|
gptkbp:composed_by
|
synthetic organic chemistry
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dissolved
|
soluble in water
soluble in DMSO
|
|
gptkbp:effective_date
|
not yet approved in all countries
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Momelotinib
|
|
gptkbp:indication
|
symptomatic splenomegaly
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_tested_for
|
Phase 3
|
|
gptkbp:lifespan
|
approximately 6 hours
|
|
gptkbp:marketed_as
|
gptkb:Jakafi
|
|
gptkbp:mechanism_of_action
|
JAK1 and JAK2 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_areas
|
hematology
|
|
gptkbp:research_status
|
ongoing studies
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
liver toxicity
cardiovascular events
thrombocytopenia
infection risk
|
|
gptkbp:status
|
gptkb:Clinical_Trials
|
|
gptkbp:structure
|
thiazole ring
pyrimidine ring
|
|
gptkbp:target_audience
|
adults
patients with myelofibrosis
|
|
gptkbp:targets
|
gptkb:Oncology
gptkb:Cyclin-dependent_kinase
|
|
gptkbp:treatment
|
with chemotherapy
with other JAK inhibitors
|
|
gptkbp:used_for
|
myelofibrosis
|
|
gptkbp:bfsParent
|
gptkb:Sierra_Oncology
|
|
gptkbp:bfsLayer
|
4
|